LB Pharmaceuticals, Inc. (LBRX)
39.42
+0.19
(+0.48%)
USD |
NASDAQ |
Oct 22, 16:00
39.77
+0.35
(+0.89%)
After-Hours: 20:00
LB Pharmaceuticals Enterprise Value : 808.04M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | 808.04M |
| October 21, 2026 | 802.59M |
| October 20, 2026 | 853.35M |
| October 19, 2026 | 790.54M |
| October 16, 2026 | 731.17M |
| October 15, 2026 | 729.74M |
| October 14, 2026 | 652.58M |
| October 13, 2026 | 675.24M |
| October 12, 2026 | 707.94M |
| October 09, 2026 | 744.94M |
| October 08, 2026 | 670.08M |
| October 07, 2026 | 657.17M |
| October 06, 2026 | 660.04M |
| October 05, 2026 | 670.37M |
| October 02, 2026 | 738.34M |
| October 01, 2026 | 746.66M |
| September 30, 2026 | 778.21M |
| September 29, 2026 | 746.66M |
| September 28, 2026 | 764.15M |
| September 25, 2026 | 748.09M |
| September 24, 2026 | 761.57M |
| September 23, 2026 | 801.44M |
| September 22, 2026 | 901.82M |
| September 21, 2026 | 910.43M |
| September 18, 2026 | 895.51M |
| Date | Value |
|---|---|
| September 17, 2026 | 886.05M |
| September 16, 2026 | 898.38M |
| September 15, 2026 | 911.86M |
| September 14, 2026 | 963.49M |
| September 11, 2026 | 957.46M |
| September 10, 2026 | 1.004B |
| September 09, 2026 | 1.045B |
| September 08, 2026 | 1.094B |
| September 04, 2026 | 1.093B |
| September 03, 2026 | 1.040B |
| September 02, 2026 | 1.097B |
| September 01, 2026 | 1.028B |
| August 31, 2026 | 1.033B |
| August 28, 2026 | 1.046B |
| August 27, 2026 | 1.051B |
| August 26, 2026 | 1.059B |
| August 25, 2026 | 1.077B |
| August 24, 2026 | 1.060B |
| August 21, 2026 | 1.043B |
| August 20, 2026 | 1.032B |
| August 19, 2026 | 1.081B |
| August 18, 2026 | 1.076B |
| August 17, 2026 | 1.003B |
| August 14, 2026 | 1.048B |
| August 13, 2026 | 947.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 5.905B |
| ANI Pharmaceuticals, Inc. | 1.929B |
| Corcept Therapeutics, Inc. | 11.30B |
| Veru, Inc. | 15.94M |
| Johnson & Johnson | 671.59B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.60M |
| Total Expenses (Quarterly) | 51.60M |
| EPS Diluted (Quarterly) | -1.712 |
| Earnings Yield | -7.56% |
| Normalized Earnings Yield | -7.576 |